Free Newsletter
Manufacturer eyes potent compounds
Swiss pharmaceutical group Helsinn has announced plans to create a competitive manufacturing organization focused on highly potent compounds that includes both R&D and production capabilities. Financial investments and a new organization of manufacturing sites in Ireland and Switzerland are part of the strategy. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: